Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
140.09
-0.28 (-0.20%)
Streaming Delayed Price
Updated: 12:14 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
50
51
Next >
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
May 28, 2024
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them.
Via
InvestorPlace
Topics
ETFs
Ozempic Maker Novo Nordisk's Increasing Influence On Denmark's Employment Raises Economic Concerns
May 28, 2024
The updated employment figures have heightened concerns about Denmark's economy becoming excessively dependent on Novo.
Via
Benzinga
Topics
Economy
Exposures
Economy
LifeMD Can Surge on Its GLP-1 Offerings
May 28, 2024
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result
Via
MarketBeat
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
May 28, 2024
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.
Via
The Motley Fool
Where Will Novo Nordisk Be in 10 Years?
May 25, 2024
Will Novo Nordisk top $1 trillion in market value?
Via
The Motley Fool
The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop
May 27, 2024
Overlooked penny stocks are the path to outsized gains and these shares seem to fit the bill at the moment.
Via
InvestorPlace
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?
May 27, 2024
European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW, Enel, Iberdrola.
Via
Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
Chinese Scientists Achieve World's First Diabetes Cure Using Cell Therapy: Report
May 27, 2024
A team of Chinese scientists has successfully cured a patient's diabetes using cell therapy, marking a global first.
Via
Benzinga
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
May 26, 2024
The gold rush for obesity medications just got a bit more intense.
Via
The Motley Fool
3 High-Flying Stocks That Could Soar Even More
May 25, 2024
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.
Via
The Motley Fool
Elon Musk Says Ozempic 'Will Become Very Cheap' After New Comedy Special Paints It As Weight Loss Drug Only Wealthy People Can Afford
May 25, 2024
Elon Musk predicts that Novo Nordisk's weight-loss drug Ozempic will eventually become very cheap, following its depiction in a new South Park special as a luxury medication accessible only to the...
Via
Benzinga
Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression
May 24, 2024
Novo Nordisk's Ozempic was used on 3,533 patients; results show a 24% reduction in kidney disease progression.
Via
Benzinga
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
May 24, 2024
Most Dow stocks are strong investments but these 7 stand out at the moment as the macroenvironment trends positive again.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
May 23, 2024
Weight loss drugs get the new parody treatment in a "South Park" streaming special.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.
May 23, 2024
The search for the next GLP-1 drugs that will be blockbuster winners during the next market cycle is on, and here are three contenders.
Via
InvestorPlace
Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
May 22, 2024
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in...
Via
Benzinga
Exposures
Product Safety
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
May 22, 2024
Compounding weight loss drugs, which are similar to brand-name medications such as Ozempic and Mounjaro, will be banned in Australia.
Via
Benzinga
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
May 22, 2024
NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide.
Via
Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
May 21, 2024
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.
Via
Benzinga
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
May 21, 2024
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."
Via
Benzinga
Topics
ETFs
3 Growth Stocks That Could Be Millionaire-Makers: May Edition
May 21, 2024
Investors wanting to get rich should consider a long-term holding in these stocks, each of which has risen exponentially in the last year.
Via
InvestorPlace
Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
May 21, 2024
Nestlé SA launches Vital Pursuit, a new food line tailored for GLP-1 weight loss medication users, featuring protein, fiber, and essential nutrients. Available Q4 nationwide.
Via
Benzinga
7 Reliable Blue-Chip Stocks That Cannot Miss
May 21, 2024
These reliable blue-chip stocks to own are the closest thing to slam dunk investments that exist. Discover why you should buy them now.
Via
InvestorPlace
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
May 21, 2024
Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1...
Via
Benzinga
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
May 20, 2024
HIMS stock is catching a bid after Hims & Hers announced that it would begin providing access to GLP-1 weight-loss injections.
Via
InvestorPlace
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars
May 20, 2024
Hims & Hers Health expands its weight loss offerings with GLP-1 injections and oral medication kits. Pricing starts at $79/month.
Via
Benzinga
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
May 20, 2024
Certain genes may predict strong responses to Novo Nordisk's Wegovy (semaglutide) in obesity treatment, with patients showing significant weight loss linked to a "hungry gut" genetic profile. This...
Via
Benzinga
Magnificent Seven? Just Two Members Meet This Earnings Criteria
May 20, 2024
These megacaps meet triple-25% growth standards.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
50
51
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.